Drugs / S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745
S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06568588 | Jan 2024 → Aug 2026 overdue | autism spectrum disorder | Universidad San Francisco de Quito | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06568588 ↗ |
| Modality | Other / unclassified | “Saccharomyces boulardii is a probiotic, in other words, a beneficial microorganism.” NCT06568588 ↗ |